Theracryf Plc

Theracryf Plc is a clinical-stage therapeutics company focused on developing treatments for oncology and behavioral brain disorders. Its pipeline includes an orexin-1 antagonist for binge eating disorder and anxiety, an atypical dopamine transporter inhibitor for fatigue and narcolepsy, and SFX-01 for glioblastoma and neurodevelopmental disorders. Formerly known as Evgen Pharma plc, it changed its name to Theracryf Plc in April 2024. Incorporated in 2014, the company is headquartered in Nether Alderley, United Kingdom.